Key facts
- This page summarizes Matthew E. Korenberg's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Feb 2024, 18:50.
Matthew E. Korenberg - 27 Feb 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)
- Reporting relationship
- PRESIDENT & CHIEF OPERATING
- Issuer ticker
- LGND
- Reported as of
- 27 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Feb 2024, 18:50:43 UTC
- Prior SEC filing
- 16 Feb 2024
- Next SEC filing
- 15 May 2024
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Andrew Reardon, Attorney-in-Fact For: Matthew E. Korenberg
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew E. Korenberg filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 29 Feb 2024.
Change
- Previous filing in this sequence was filed on 16 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LGND
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +14,416
- Change %
- +16%
- Price
- $0.000000
- Shares after
- 103,861
- Date
- 27 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LGND
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +58,544
- Change %
- Price
- $0.000000
- Shares after
- 58,544
- Date
- 27 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 58,544
- Exercise price
- $89.20
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Footnote F2
The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.